Trey Mullikin is an Oncology physician affiliated with Duke University. OpenAlex indexes 107 publications with 1,387 citations (h-index 17); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20 Medicine Circle
Durham, NC 277100001
Telephone
919-668-6680Provider last certified this registry record 15 Oct 2021.
Clinical trials
- Lattice Radiotherapy for Adults With Large Tumors
Sponsor: Duke University
- Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases
Sponsor: Duke University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galvanize Therapeutics, IncProgram year20241 payment
- Telix PharmaceuticalsProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
54.2%Corticosteroid54.2%Dexamethasone100%Part D≥26 patientsMetabolism & gastrointestinal
23.7%Corticosteroid23.7%Prednisone100%Part D<11 patientsNervous system
22%N-methyl-D-aspartate Receptor Antagonist22%Memantine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Journal of the National Comprehensive Cancer Network
2025 - Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”